Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naive and vaccinia-immune individuals

被引：77

作者：

Parrino, Janie

McCurdy, Lewis H.

Larkin, Brenda D.

Gordon, Ingelise J.

Rucker, Steven E.

Enama, Mary E.

Koup, Richard A.

Roederer, Mario

Bailer, Robert T.

Moodie, Zoe

Gu, Lin

Yan, Lihan

Graham, Barney S.

机构：

[1] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA

[2] Stat Ctr HIV AIDS Res & Prevent, Seattle, WA USA

[3] EMMEs Corp, Rockville, MD USA

来源：

VACCINE | 2007年 / 25卷 / 08期

关键词：

smallpox; orthopoxvirus; vaccine;

D O I：

10.1016/j.vaccine.2006.10.047

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax (R) in vaccinia-naive and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax (R) challenge at 3 months. Two or more doses of MVA prior to Dryvax (R) reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax (R) vaccinia-specific CD8+ T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax (R) vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopox viruses. Published by Elsevier Ltd.

引用

页码：1513 / 1525

页数：13